10th December 2023NovalGen presents NVG-111 clinical data in hematological malignancies in an oral session and preclinical data for next-generation AR T cell engager NVG-222 at the 65th American Society of Hematology Annual Meeting
2nd November 2023NovalGen announces one oral and one poster presentation at the 65th American Society of Hematology Annual Meeting
3rd November 2022NovalGen announces one oral and two poster presentations at the American Society of Hematology Annual Meeting
26th May 2022NovalGen announces compelling data from the Phase 1/2 Study of NVG-111 at the ASCO Annual Meeting
17th September 2021NovalGen announces data presentation at the Upcoming XIX International Workshop on Chronic Lymphocytic Leukemia
9th June 2021NovalGen doses first patient in Phase I study in Chronic Lymphocytic Leukemia & Mantle Cell Lymphoma
20th May 2021NovalGen presents data at American Society of Clinical Oncology for novel ROR1xCD3 bispecific antibody for non-Hodgkin lymphoma
7th April 2021NovalGen receives CTA approval to start a Phase 1/2 first in human study to evaluate the safety, pharmacokinetics and efficacy of NVG-111 in Chronic Lymphocytic Leukemia & Mantle Cell Lymphoma
